Article info
PDFCorrespondence
Correspondence on ‘Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement’
- Correspondence to Dr Ankur Kumar Jindal, Allergy Immunology Unit, Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India; ankurjindal11{at}gmail.com
Citation
Correspondence on ‘Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement’
Publication history
- Received January 12, 2021
- Accepted January 15, 2021
- First published March 4, 2021.
Online issue publication
October 18, 2023
Article Versions
- Previous version (18 October 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.